The legal action follows a series of disclosures that severely impacted the company’s market valuation. In June 2026, reports surfaced that the Brussels Public Prosecutor’s Office was investigating Wise’s European entity regarding suspicious transactions exceeding $582.5 million. Prosecutors cited potential links to corruption, fraud, and international drug trafficking. Following these reports, the company’s stock price dropped by nearly 10% over two consecutive trading days.

Regulatory scrutiny intensified on July 24, 2026, when U.S. officials denied the firm's application for a national trust bank license. Regulators explicitly pointed to deficiencies in Wise’s protocols for combating money laundering and terrorism financing. This disclosure triggered a further 6.2% decline in share price, closing at $11.33. Investors seeking to participate in the Pomerantz LLP class action may contact Danielle Peyton to review their eligibility and the specific allegations regarding breaches of fiduciary duty.